YPrime COO Alison O'Neill -'pursue what you enjoy and be flexible'
Sep 18, 2024 · She brings her global experience across multiple therapeutic areas to her current role leading operations at YPrime. In this position, Alison oversees project management and all teams responsible for the quality of project delivery - she ensures the excellence of services provided to sponsors, sites, and patients.
GLP-1 market heats up as companies vie for next-gen obesity drugs
Oct 31, 2024 · Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly grown.
Vetter Pharma International
Vetter is a leading global contract development and manufacturing organization (CDMO) for the aseptic production of injectables. Our headquarters are in Ravensburg, Germany, where we have been a family-owned company since our start as a pharmacy in 1950.
Eli Lilly expansion set to add 750 skilled jobs to Wisconsin site
Dec 10, 2024 · “Today’s announcement represents our single largest US manufacturing investment outside our home state of Indiana and will add to our ability to expand capacity to make both our existing and future pipeline of medicines right here in the Midwest,” said Edgardo Hernandez, executive VP and president, manufacturing operations, Eli Lilly.
Körber absorbs Bähren to expand pharma packaging
Dec 3, 2024 · The pharmaceutical business unit of the German giant Körber has snapped up the compatriot label and leaflet supplier Wilhelm Bähren GmbH & Co as the pharmaceutical packaging market is set to double in the coming decade.
Adragos Pharma snaps up Baccinex to expand CDMO network
Nov 26, 2024 · Back in April this year, Raabe told Outsourcing Pharma that the company is on the lookout for strategic acquisitions with the mission to double or even triple its size in the coming years.. Adragos focuses its CDMO efforts on small molecule treatments, which are seeing a resurgence of interest even as biologics and cell and gene therapies generate big excitement in the biotech industry.
AbbVie set to file for FDA approval on tavapadon
Dec 10, 2024 · Dopamine receptors. By activating the dopamine receptors with dopamine agonists, some of the symptoms of Parkinson’s disease can be treated. Currently, D2/D3 dopamine receptor agonists tend to be used in this respect; they can cause common adverse effects, such as excessive sleeping during the day, confusion, hallucinations, light-headedness, low blood pressure, uncontrolled movements, or ...
Gilead taps into Terray’s AI-based drug discovery
Dec 19, 2024 · “Next-generation, AI-driven platforms using custom-generated large, relevant data sets will serve as important tools in our efforts to shape the future of drug discovery in our ongoing pursuit of innovative treatments across our therapeutic areas of focus,” said Flavius Martin, Gilead’s executive vice president of research, in a public statement.
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.
Trialbee -on a mission of improving patient recruitment
Apr 4, 2024 · MW: Our partnership stemmed from discussions we initiated in the fall. We recognized synergies between our businesses, particularly in the realm of oncology studies. While we're open to additional partnerships, we already have numerous collaborations in progress, spanning various sectors such as online disease communities, patient cooperatives, and …